Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

By J. Moon, W. McKenna, J. McCrohon, P. Elliott, Gillian Smith, D. Pennell. Journal of the American College of Cardiology, 2003

784 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/214f7f25bb78029dfd1ba038fbbccae14c1da3d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. Spirito
2. B. Maron
3. C. Seidman
4. Judith Hochman
5. M. Maron

In Radiology, Nuclear Medicine and Imaging

1. Detlef Lohse
2. Xuehua Zhang

Citations in the corpus

• The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (2004, background): “Regions of myocardial late gadolinium enhancement lso occur in hypertrophic cardiomyopathy (HCM) (3), and he extent of enhancement has been associated with clinical arkers of sudden death risk and progression to heart ailure (4).”
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G (2003, background): “LV may represent an additional diagnostic modality (69)”